PDF(Sci-hub)
Abstract：
The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.
摘要：
冠状病毒病(COVID-19)大流行导致了一场全球斗争，以应对庞大的感染者数量，其中许多人需要重症监护支持或最终屈服于疾病。疫情是通过公共卫生措施控制疾病和对受影响者的支持性护理相结合来管理的。迄今为止,没有特异性的抗COVID-19治疗。然而,确定可以扭转潮流的治疗方法的紧迫性导致了几种研究药物的出现，作为改善结果的潜在候选药物，特别是在严重到危重的情况下。虽然许多这些辅助药物正在临床试验中进行研究，专业机构试图澄清这些药物的使用可能被视为非标签或同情使用的背景。这篇综述总结了COVID-19患者使用研究性辅助治疗的临床证据，以及国际和国家医疗保健组织发布的指南中对其使用的建议。
